Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial).

Arndt Stahler,Sebastian Stintzing,Dominik Paul Modest,Ivan Jelas,Kathrin Heinrich,Lisa Miller-Phillips,Jobst C. von Einem,Ursula Vehling-Kaiser,Thomas Decker,Alexander Kiani,Ludwig Fischer von Weikersthal,Tobias Heintges,Christoph Kahl,Frank Kullmann,Werner Scheithauer,Markus Moehler,Pratyaksha Wirapati,Thomas Kirchner,Andreas Jung,Volker Heinemann

Association of MAPK signaling subtypes with prognostic benefit for bevacizumab in left-sided metastatic colorectal cancer (mCRC) patients treated with FOLFIRI + cetuximab / bevacizumab (FIRE-3 trial).

2019

3584Background: We investigated the role of the MAPK pathway by mRNA expression profiles in microarrays of the FIRE-3 trial as it was formerly associated with prognosis. Methods: 451 patients provi...

Keywords:

Cetuximab
Oncology
FOLFIRI
Bevacizumab
Colorectal cancer
Pathology
Internal medicine
MAPK/ERK pathway
Medicine
mrna expression
mapk signaling
left sided

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations